knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 15:28:22 - browse：9

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Why patients can’t get everything they want on drug pricing

WSS

How doctors’ personal politics affect patients

Will the FTC rein in IQVIA's health data empire?

Take antibiotics after sex, CDC recommends for certain risk groups

Eli Lilly’s Zepbound improved liver scarring in mid

How doctors’ personal politics affect patients

In the gardens at Boston Children's Hospital, families find sanctuary

Wikipedia

knowledge

focus

Cancer drug shortages should be causing more outrage

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

23andMe had bad news about my health. I wish a person had delivered it

Eli Lilly’s Zepbound improved liver scarring in mid

In Memoriam: Notable people who died in 2023

Congress needs to close a vaccine

Hepatitis C has a cure — but many Americans still lack access to it

Stopping antidepressants leads to symptoms for 1 in 6 patients

Dobbs anniversary: the lost opportunity of abortion as health care

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Wikipedia

What to watch for from Zogenix and Amicus clinical trials

Truvian presents data for its desktop blood

A new initiative will help leaders fight the next pandemic

The most pressing bird flu mysteries scientists want answered

What it's like to live with paralysis for one psychologist

Dems pitch expanding Medicare power to negotiate drug prices

leisure time

explore

leisure time

explore